Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decrease in Short Interest

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 18,600 shares, a decrease of 42.2% from the December 31st total of 32,200 shares. Based on an average trading volume of 31,600 shares, the short-interest ratio is currently 0.6 days. Currently, 0.6% of the company’s stock are short sold.

Artelo Biosciences Stock Performance

ARTL stock traded up $0.01 during midday trading on Thursday, hitting $1.19. 8,600 shares of the company’s stock were exchanged, compared to its average volume of 21,568. Artelo Biosciences has a one year low of $0.91 and a one year high of $1.75. The stock’s fifty day moving average price is $1.10 and its 200-day moving average price is $1.18. The company has a market cap of $3.84 million, a PE ratio of -0.41 and a beta of 1.25.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, analysts expect that Artelo Biosciences will post -1.99 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Artelo Biosciences in a report on Monday, December 9th. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. Finally, D. Boral Capital reissued a “buy” rating and issued a $6.00 price target on shares of Artelo Biosciences in a report on Tuesday, January 14th.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.